Table 1.
Neutralizing antibody analysis. Serum samples collected at sacrifice from Cohorts 1 and 2 (n = 30) were analyzed for neutralizing antibody activity using TZM-bl assay against the control virus SVA-MLV, HIV-BaL.26, and HIV MN.3. Values reported above are the serum dilution at which relative luminescence units (RLUs) were reduced 50% as compared with virus control wells (no serum). Titers against HIV are considered positive for neutralizing antibody activity based on the criterion of signal >3x that against the negative control virus and >3x the signal of animals in the vaccine control group. No statistical differences were found between groups.
| Specimen ID | Specimen Collection Time |
SVA-MLV Negative Control |
HIV-MN.3 Clade B Tier 1a |
HIV-BaL Clade B Tier 1b |
|---|---|---|---|---|
| PBS 1 | 10 days post-boost 1 | 59 | 180 | 49 |
| PBS 2 | <20 | <20 | <20 | |
| PBS 3 | 48 | 134 | 44 | |
| PBS 4 | 72 | 220 | 39 | |
| PBS 5 | 22 | 22 | 30 | |
| PBS 6 | 7 days post-boost 2 | 220 | 302 | 474 |
| PBS 7 | 25 | <20 | 37 | |
| PBS 8 | <20 | 55 | 23 | |
| PBS 9 | <20 | 25 | <20 | |
| PBS 10 | <20 | 55 | 21 | |
| VLP 1 | 10 days post-boost 1 | 22 | 185 | 57 |
| VLP 2 | <20 | 217 | 21 | |
| VLP 3 | <20 | 66 | 34 | |
| VLP 4 | <20 | 129 | 26 | |
| VLP 5 | 27 | 104 | 39 | |
| VLP 6 | 7 days post-boost 2 | <20 | 233 | <20 |
| VLP 7 | <20 | 121 | 34 | |
| VLP 8 | <20 | 198 | <20 | |
| VLP 9 | 65 | 255 | 78 | |
| VLP 10 | 24 | 137 | 44 | |
| VLP + anti-CTLA-4 Ab 1 | 10 days post-boost 1 | <20 | 55 | 25 |
| VLP + anti-CTLA-4 Ab 2 | <20 | <20 | 22 | |
| VLP + anti-CTLA-4 Ab 3 | <20 | 77 | 35 | |
| VLP + anti-CTLA-4 Ab 4 | 22 | 243 | 27 | |
| VLP + anti-CTLA-4 Ab 5 | 77 | 148 | 90 | |
| VLP + anti-CTLA-4 Ab 6 | 7 days post-boost 2 | <20 | <20 | <20 |
| VLP + anti-CTLA-4 Ab 7 | <20 | <20 | <20 | |
| VLP + anti-CTLA-4 Ab 8 | <20 | 203 | <20 | |
| VLP + anti-CTLA-4 Ab 9 | <20 | 248 | <20 | |
| VLP + anti-CTLA-4 Ab 10 | <20 | 284 | <20 |